Key Takeaways
- A brutal quarter, but self-inflicted: Revenue collapsed to ₹640 crore (from ₹860 crore in Q4) because management consciously halted dispatches to customers who could not pay, prioritizing cash over volume.
- Profitability cratered: PAT fell to ₹5.34 crore from ₹84.1 crore YoY, hit by the revenue drop, GenX fixed costs with no revenue, site-related expenses, and poor fixed-cost absorption.
- The order book is holding, just: Order intake of ₹795 crore is in the guided range, but domestic greenfield ethanol orders are slowing as India’s EBP20 target is met, and U.S. tariff uncertainty is freezing GenX decisions.
- The GenX bet is now a liability: The U.S. facility is operational but generating no revenue; the additional 25% tariff kicks in August 28, and management cannot yet quantify the damage or the alternative use plan.
- What to watch next quarter: Whether the tariff picture clarifies by end-August, whether the GenX alternative-use study delivers a credible plan, and whether H2 profitability actually recovers as promised.
The Revenue Collapse: A Conscious Cash Call
- Dispatch halt, not demand destruction: Revenue fell ₹220 crore QoQ because Praj refused to ship goods to customers without cash on the table, as liquidity-strained clients accumulated inventory and receivables.
- The liquidity trap: Customers have sanctioned bank loans, but bankers want to see progress across the entire project before disbursing, and delays in other vendors’ work or civil work freeze Praj’s own dispatches, elongating the execution cycle.
- Domestic ethanol slowdown: India achieved its EBP20 target ahead of schedule, and excess installed capacity now exceeds the 20% blending requirement, causing a temporary slowdown in conversion of inquiries into firm orders for new greenfield ethanol plants.
- International delays: A good inquiry basket from the Americas exists, but order bookings are delayed by tariff-related developments; 45Z policy clarity is encouraging, but tariff uncertainty remains a headwind.
- Services and CBG provide some offset: The services business continues on a healthy growth path with a good inquiry pipeline for biogenic CO2 capture solutions, and the CBG pipeline is healthy, though decision-making is delayed due to financial challenges at customers.
Sachin Raole: "That was the main reason when we took a decision that we don't want to keep on dispatching the goods to our customers without having cash on table. That is what has actually affected the revenue coming down from last quarters of 860 to 640 of this quarter. So, that was a very conscious call which we took, that if we are not seeing the money on the table, we will not continue with dispatches of the goods."
GenX: The Tariff Shock and the Search for a Plan B
- A facility with costs but no revenue: GenX fixed costs are running while revenue activity is minimal because tariff uncertainty and reduced prioritization of energy transition projects have put projects on hold or delayed them.
- The August 28 cliff: An additional 25% U.S. tariff is set to kick in from August 28, and management says it is premature to estimate what GenX order booking will be until the scenario plays out.
- Alternatives being studied, but no answers yet: Praj is working on utilizing GenX capacity by looking at new regions or new industries, but the study will take another quarter, and other energy transition sectors like green hydrogen and green ammonia have also slowed.
- Mangalore facility under review: Controllable measures are being re-looked, including order pipeline analysis and cost structure review, but the exercise is not complete and the tariff scenario is still evolving; management will be in a better position to comment after August.
- Two more framework agreements signed: New clients inspected the facility and signed framework agreements during the quarter, but these have not yet converted to revenue-generating orders.
Sachin Raole: "It is a little premature to answer the question whether what will be the order booking for GenX at this point of time for a simple reason, because that additional 25% tariff is supposedly to kick in from, what, 28th of August. So, we will have to wait and watch for some more time to find out how this entire scenario is going to play out for us."
Margins: An Aberration, With a Promise of Recovery
- The margin walk of pain: EBITDA margin collapsed to 4.9% because of a ₹220 crore top-line drop causing fixed-cost under-recovery, GenX facility costs with no revenue, and a spike in site-related expenses from labor challenges at a couple of sites.
- Management calls it an aberration: The CFO explicitly stated this quarter is not the new normal and that the new normal will be completely different, aiming for high single-digit EBITDA percentages.
- Recovery timeline: Some pains may continue through Q2, but from Q3 (H2 onwards) the situation is not expected to continue, as existing orders and international orders booked in the March quarter and this quarter will start full-fledged execution.
- Profit remains a top focus: Management states profit is one of the top focus areas and it will take action to maintain a certain level of bottom line, though no specific margin number was committed beyond the high single-digit EBITDA aim.
Sachin Raole: "Whether this is a new normal or new normal is going to be different? According to us, yes, new normal is going to be completely different. This is like an aberration in this quarter... We are not expecting this situation to continue definitely. Some pains might continue till quarter 2, but from quarter 3, from H2 onwards, we are not expecting this situation to continue."
Order Book: Holding Steady, But the Mix Is Shifting
- Order intake in the guided zone: ₹795 crore of order intake was booked, and management says it is fair to assume the current ~₹800 crore quarterly run rate is sustainable based on the inquiry pipeline, though decisions can get delayed.
- The domestic greenfield engine is sputtering: If no additional blending mandate materializes, the domestic order book run rate in the current zone will not continue because there will be very few greenfield orders; the existing order book is roughly 80% greenfield and 20% brownfield.
- The policy catalyst everyone is waiting for: Discussions are ongoing regarding additional blending mandates beyond 20%, and management believes such an announcement would improve conversion of inquiries into orders, though it probably will not happen in the immediate future or this quarter.
- International orders provide a bridge: Orders received from international markets in the March quarter and this quarter will start full-fledged execution from H2, supporting the profitability recovery.
- No CBG firm orders booked this quarter: Despite a healthy pipeline and traction for press mud-based plants, no firm CBG order was booked in the past quarter.
Ashish Gaikwad: "You have seen that our current order booking is in that range, what you mentioned. We, of course, aim higher, based on the inquiry pipeline that we see, but the decisions can sometimes get a bit delayed. So, that is what I can say at this point in time, that it is fair to assume that type of a run rate."
New Growth Vectors: Planting Seeds for the Next Cycle
- Bio-bitumen as a CBG differentiator: Praj is developing a unique combined CBG and Bio-bitumen plant offering that enhances ROI and reduces payback period for CBG plant investors, with discussions already initiated with customers.
- Bioplastics (PLA) ready for market: The collaboration with Uhde (Thyssenkrupp) enables end-to-end Polylactic acid facilities; the technology is available now and firm offers are being made to customers.
- Diesel blending: a 2.5x larger opportunity: Management believes diesel can have a blending mandate similar to ethanol, with iso-butanol as the preferred drop-in fuel; experiments with certifying agencies are showing encouraging results, and diesel usage in India is 2.5x to 3x that of petrol.
- Value-added co-products for existing plants: Praj is developing add-on modules like the Distillers Corn Oil module for corn-based ethanol plants and rice protein extraction from rice-feedstock plants, giving existing producers extra income streams.
- SAF and 2G milestones: Praj received a detailed engineering order for a commercial-sized SAF plant in the USA and is working toward making its first 2G plant operational by the end of the year, with two more projects already in execution.
- State-level policy tailwinds: Maharashtra announced a bioenergy policy promising ₹28,000 crore in investments over five years, and Uttar Pradesh is expected to come up with a Sustainable Emission Fuel Manufacturing Promotion Policy.
Ashish Gaikwad: "this is a unique offering that Praj is developing where we are able to give a combined offering of production of CBG as well as Bio-bitumen, which enhances the return on investment and also reduces the payback period for the CBG plant investors"
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Margin recovery | High single-digit EBITDA percentage; current quarter is an "aberration" | H2 FY26 (from Q3 onwards) |
| First 2G plant operational | First 2G plant to be operational, building market confidence | By end of calendar year |
| GenX clarity | Better position to comment on tariff impact and Mangalore controllables | After August (next conversation) |
| GenX alternative-use plan | Study of new regions or industries for GenX capacity utilization | May take a quarter more |
| International order execution | Orders from March quarter and Q1 to start full-fledged execution | H2 FY26 |
| Vision 2030 | Fundamentals and growth vectors intact; committed to delivering targeted numbers | 2030 |
| Order book run rate | Fair to assume ~₹800 crore quarterly run rate is sustainable based on inquiry pipeline | Ongoing, subject to policy |
| Domestic greenfield orders | Run rate will not continue if no additional blending mandate | Conditional on policy |
Key Metrics
| Metric | Q1 FY26 |
|---|---|
| Consolidated income from operations | ₹640 cr, compared to ₹699 cr in Q1 FY25 |
| PBT before exceptional items | ₹9.61 cr, compared to ₹78.88 cr in Q1 FY25 |
| Profit after tax | ₹5.34 cr, compared to ₹84.1 cr in Q1 FY25 |
| EBITDA margin | 4.9%, drop in top line by almost ₹220 cr vs March quarter and GenX fixed costs cited |
| Effective tax rate | 44%, due to deferred tax asset on Praj GenX losses at lower rate |
| Revenue mix | 60% Bioenergy, 28% Engineering, 12% PHS |
| Export revenue share | 39% of Q1 FY26 revenue |
| Order intake | ₹795 cr, 55% domestic; mix: 80% Bioenergy, 12% Engineering, 8% PHS |
| Order backlog | ₹445 cr as of 30 June 2025, 62% domestic |
| Cash in hand | ₹450 cr as of 30 June 2025 |
| Final dividend | 300% per share, approved by shareholders |
| GenX firm proposals with customers | More than ₹1,000 cr, ~70% for U.S. customers, ~30% for non-U.S. (European region); decision-making pending |
| GenX revenue contribution so far | ~₹20 cr of top line |
| U.S. revenue contribution | Less than 10% of Praj's revenue |